Leukocidin

Leukocidin refers to a family of **bi-component pore-forming toxins** secreted by bacteria such as *Staphylococcus aureus*.[2][5][7] These toxins are key virulence factors that facilitate **immune evasion** by selectively binding to and lysing host immune cells—including neutrophils, monocytes, macrophages, phagocytes, and some lymphocytes—by creating pores in their cell membranes.[2][4][6] Each leukocidin consists of two subunits: the S (slow) subunit, which binds specific cell-surface protein receptors (often integrins or G protein-coupled receptors), and the F (fast) subunit, which associates with the S subunit to initiate pore assembly.[2][6][8] After receptor binding and heterodimerization, several dimers oligomerize to form a **lytic octameric β-barrel pore** in the host cell membrane, resulting in rapid cell lysis and necrotic death.[1][2][5][6] Known variants include **Panton-Valentine leukocidin (PVL/LukSF)**, **LukED**, **LukGH (also called LukAB)**, and **gamma-hemolysins (HlgAB, HlgCB)**, each with distinct cell and species specificity determined by recognition of unique receptors.[5][6][8] Leukocidins contribute to the pathogenesis of serious conditions such as **necrotizing pneumonia**, **skin infections**, and severe invasive infections, notably those caused by community-associated MRSA (CA-MRSA).[4][5][7] No direct small-molecule leukocidin inhibitors are currently in clinical use, but therapeutic strategies involving antitoxins and vaccines are being pursued to curtail toxin-mediated virulence and disease severity in *S. aureus* infections[7].

Other names

Bi-component pore-forming toxinStaphylococcal leukocidinPanton-Valentine leukocidin (PVL)γ-hemolysin (HlgAB, HlgCB)LukEDLukGH (LukAB)LukPQLukMF’

Pore formation in immune cell membranes via stepwise oligomerization after receptor binding, leading to lysis and cell death[2][3][6].